Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 169

The DOI matches its Crossref record.

Loss of SFRP1 is associated with breast cancer progression and poor prognosis in early stage tumors

Klopocki, Eva, Kristiansen, Glen, Wild, Peter, Klaman, Irina, Castanos-Velez, Esmeralda, Singer, Gad, Stöhr, Robert, Simon, Ronald, Sauter, Guido, Leibiger, Haike, Essers, Lutz, Weber, Birgit, Hermann, Klaus, Rosenthal, André, Hartmann, Arndt, Dahl, Edgar·2004·International Journal of Oncology

Abstract

Aberrant activation of the Wnt signaling pathway plays an important role in the development of solid tumors such as breast and colon cancer. Secreted Frizzled-related protein 1 (SFRP1) is a negative regulator of the Wnt pathway. It has been described that SFRP1 mRNA is strongly down-regulated in breast cancer and a putative tumor suppressor function has been postulated. We have generated and characterized an SFRP1 specific antibody to analyze its expression on protein level and to investigate the association of SFRP1 expression with clinicopathological parameters and patient survival. Analysis of >2000 invasive breast tumors and 56 carcinoma in situ revealed similar frequencies of SFRP1 loss in these tumors (46% and 43% respectively). Therefore, we propose that loss of SFRP1 expression is an early event in breast tumorigenesis. SFRP1 expression was inversely correlated with tumor stage (p<0.001) but not with tumor grade (p=0.14) or lymph node status (p=0.84). Performing a multivariate analysis we could confirm the association between tumor stage and SFRP1 expression (p=0.029). In particular, loss of SFRP1 expression in early stage breast tumors (pT1) was associated with poor prognosis (p=0.04). In conclusion, expression of SFRP1 is commonly lost in breast cancer. SFRP1 expression might be useful as a novel prognostic marker in early stage breast cancer.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3892/ijo.25.3.641

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 169

Metadata

Authors
Klopocki, E., Kristiansen, G., Wild, P., Klaman, I., Castanos-Velez, E., Singer, G., Stöhr, R., Simon, R., Sauter, G., Leibiger, H., Essers, L., Weber, B., Hermann, K., Rosenthal, A., Hartmann, A., & Dahl, E.
Venue
International Journal of Oncology
Published
2004-09-01
Volume
25
Issue
3
Pages
641-9
ISSN
  • 1019-6439 (ISSN-L)
  • 1791-2423
OpenAlex
W1974141553
Cited by
169
References
0
FWCI
3.50
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Loss of SFRP1 is associated with breast cancer progression and poor prognosis in early stage tumors. https://app.cochat.ai/papers/10.3892/ijo.25.3.641
The paper
Klopocki, E., Kristiansen, G., Wild, P., Klaman, I., Castanos-Velez, E., Singer, G., Stöhr, R., Simon, R., Sauter, G., Leibiger, H., Essers, L., Weber, B., Hermann, K., Rosenthal, A., Hartmann, A., & Dahl, E. (2004). Loss of SFRP1 is associated with breast cancer progression and poor prognosis in early stage tumors. International Journal of Oncology. https://doi.org/10.3892/ijo.25.3.641

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.